Back to top

Image: Bigstock

Osiris Therapeutics, Inc.

Read MoreHide Full Article

Osiris’ third quarter loss was wider-than-expected. The company also reported that certain factors impacted third quarter revenues. Although we are encouraged by the company's efforts to grow the Biosurgery segment, Osiris’ dependence on a single segment for growth is concerning. Moreover, Osiris is evaluating Grafix for additional indications and disappointing data would have an adverse impact on the shares. Meanwhile, we are positive on Osiris’ deals with Arthrex and Stryker for Cartiform and BIO4, respectively. We are also positive on the company’s sale of its ceMSC business which has not only brought in cash in the form of an upfront payment but will also bring in royalties. Expanded sales force, improving Medicare and private reimbursement cover should drive revenues.

Published in